BD (Becton, Dickinson and Company) announced on April 9, 2025, that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its advanced microbiology solution. This solution integrates the BD Phoenix™ M50 Automated Microbiology System, BDXpert™ System, and BD Synapsys™ Informatics Solution.
The integrated system leverages rapid identification (ID) and antimicrobial susceptibility testing (AST) algorithms to assist in interpreting complex diagnostic data. This capability helps ensure accurate and reliable diagnoses related to antimicrobial resistance (AMR), a global health concern contributing to nearly five million deaths annually.
The BDXpert™ system, when integrated with BD Synapsys™ and BD Phoenix™ M50, aims to streamline data management, reduce potential errors, and provide critical test results to clinicians more efficiently. This advancement supports clinical microbiology laboratories in addressing challenges like understaffing and increased testing demands.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.